Heme oxygenase-1 is not decreased in preeclamptic placenta and does not negatively regulate placental soluble fms-like tyrosine kinase-1 or soluble endoglin secretion

S Tong; TJ Kaitu'u-Lino; K Onda; S Beard; R Hastie; NK Binder; C Cluver; L Tuohey; C Whitehead; F Brownfoot; M De Silva; NJ Hannan

Journal article

Heme oxygenase-1 is not decreased in preeclamptic placenta and does not negatively regulate placental soluble fms-like tyrosine kinase-1 or soluble endoglin secretion

S Tong, TJ Kaitu'u-Lino, K Onda, S Beard, R Hastie, NK Binder, C Cluver, L Tuohey, C Whitehead, F Brownfoot, M De Silva, NJ Hannan

Hypertension | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015

DOI: 10.1161/HYPERTENSIONAHA.115.05847

Abstract

Elevated placental release of the antiangiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG), is central to the pathophysiology of preeclampsia. It is widely accepted that heme oxygenase-1 (HO-1) is decreased in preeclamptic placenta and negatively regulates sFlt-1 and sENG production. We set out to verify these contentions. There was no difference in HO-1 mRNA or protein levels in preterm preeclamptic placentas (n=17) compared with gestationally matched controls (n=27). In silico analysis of microarray studies did not identify decreased placental HO-1 expression in preeclamptic placenta. Silencing HO-1 in primary trophoblasts did not affect sFlt-1 protei..

View full abstract

University of Melbourne Researchers

Stephen Tong Author

Tu'uhevaha Kaitu'u-Lino Author

Natalie Binder Author

Clare Whitehead Author

Related Projects (5)

Mother and baby communication during early pregnancy, the key to establishing a healthy pregnancy

Soluble endoglin in the pathogenesis of preeclampsia: investigation of mechanisms and the development of therapeutics

Preeclampsia is a severe disease of pregnancy. As the pathogenesis is poorly understood, the only treatment is for clinicians to deliver bab..

DEVELOPING MOLECULAR THERAPEUTICS AND DIAGNOSTICS FOR PREGNANCY COMPLICATIONS

Pregnancy complications still causes the death of mothers, and their babies. During this fellowship, we will be developing new treatments an..

TARGETING THE TOXINS OF PREECLAMPSIA

Preeclampsia is a severe disease of pregnancy - the placenta releases toxins in to mum's bloodstream that circulate her body and damage her ..

DEVELOPING DIAGNOSTICS AND THERAPEUTICS FOR PREECLAMPSIA: TARGETING A NOVEL PLACENTAL SPECIFIC SFLT-1 VARIANT

Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protei..

Grants

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

This study was funded by grants (no. 1061977 and 1048707) and received salary support (no. 1050765, 1062418, and 628927) from the National Health and Medical Research Council of Australia and by the University of Melbourne Research CR Roper Fellowship (to N.J. Hannan).